Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis
- 30 January 2021
- journal article
- research article
- Published by Anticancer Research USA Inc. in Anticancer Research
- Vol. 41 (2), 1055-1062
- https://doi.org/10.21873/anticanres.14862
Abstract
Background/aim: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients. Patients and Methods: Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups. Results: The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group. Conclusion: The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.Keywords
This publication has 24 references indexed in Scilit:
- Challenges of Guarantee-Time BiasJournal of Clinical Oncology, 2013
- Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancerAsia-Pacific Journal of Clinical Oncology, 2010
- Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatmentAnnals of Oncology, 2010
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)Epidemiology, 2007
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesPLoS Medicine, 2007
- A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimensBritish Journal of Cancer, 2006
- Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301Journal of Clinical Oncology, 2006
- Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First LineJournal of Clinical Oncology, 2005